Assessment of risk of developing myocardial infarction in patients
Assessment of risk of developing cardiovascular disease or ischemic
Immunoturbidimetry
C Reactive Protein (CRP), Cardiac
C Reactive Protein, High Sensitivity
C-Reactive Prot, High Sens, Serum
C-Reactive Protein (CRP)
C-Reactive Protein, Cardio
C-Reactive Protein, Sensitive
Cardio C-Reactive Protein
CRP Cardiac
CRP, High Sensitivity
CRP, Highly Sensitive, (hs-CRP), Serum
CRP, Ultra-Sensitive, Serum
High-Sensitivity C-Reactive Protein (hs-CRP)
Protein, C-Reactive
Sensitive C-Reactive Protein
Ultra-Sensitive C-Reactive Protein (CRP)
Serum
This assay should be used to assess risk of cardiovascular disease or events.
To monitor or assess other inflammatory disorders, order CRP / C-Reactive Protein (CRP), Serum.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.
0.2 mL
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 7 days | |
Frozen | 30 days |
Assessment of risk of developing myocardial infarction in patients
Assessment of risk of developing cardiovascular disease or ischemic
C-reactive protein (CRP) is a biomarker of inflammation. Serum CRP concentrations increase rapidly and dramatically (100-fold or more) in response to tissue injury or inflammation. High-sensitivity CRP (hs-CRP) is more precise than standard CRP when measuring baseline (ie, normal) concentrations and enables a measure of chronic inflammation.
Atherosclerosis is an inflammatory disease and hs-CRP has been endorsed by multiple guidelines as a biomarker of atherosclerotic cardiovascular disease risk.(1-3)
A large prospective clinical trial demonstrated significantly less cardiovascular risk for patients with hs-CRP less than 2.0 mg/L.(1) More aggressive treatment strategies may be warranted in patients with hs-CRP of 2.0 mg/L or higher.
> or =18 years: <2.0 mg/L
Reference values have not been established for patients who are younger than 18 years.
Values greater than 2.0 mg/L suggest an increased likelihood of developing cardiovascular disease or ischemic events.
This test is recommended for cardiovascular risk assessment only.
C-reactive protein (CRP) is an acute-phase reactant and has high intra-individual variability. Therefore, a single test for high-sensitivity CRP (hs-CRP) may not reflect an individual patient's basal hs-CRP level. Repeat measurement may be required to firmly establish an individual's basal hs-CRP concentration. The lowest of the measurements should be used as the predictive value.
Because CRP is an acute-phase reactant, measurements in apparently healthy individuals may not truly reflect the basal level if inflammation is present.
This hs-CRP assay should be used to assess risk of cardiovascular disease or events. A different CRP test (CRP / C-Reactive Protein [CRP], Serum) should be used to monitor or assess other inflammatory disorders.
Significantly decreased CRP values may be obtained from samples taken from patients who have been treated with carboxypenicillins.(4)
No significant interference is seen from rheumatoid factors up to a concentration of 200 IU/mL.
1. European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818
2. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014;129:S49-S73
3. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8:473-488
4. Cardiac C-Reactive Protein (Latex) High Sensitive. V 12.0. Package insert: Roche Diagnostics; 03/2019
5. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL-cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175-1182
6. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140:563-595
7. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511. doi:10.1161/01.cir.0000052939.59093.45
This is a particle-enhanced immunoturbidimetric assay. Human C-reactive protein (CRP) agglutinates with latex particles coated with monoclonal anti-CRP antibodies. The precipitate is determined turbidimetrically.(Package insert: Cardiac C-Reactive Protein (Latex) High Sensitive. Roche Diagnostics; V15.0, 04/2024)
Monday through Saturday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
86141
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
HSCRP | C-Reactive Protein, High Sens, S | 30522-7 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
HSCRP | C-Reactive Protein, High Sens, S | 30522-7 |